Enrofloxacin (EFX) is one of the 2nd generation quinolone antibiotics and is now widely used as a broad-spectrum antibiotic for industrial animals. Previous study showed that EFX reduces the cellular metabolic activity of spleen cells and modulates the inflammatory responses. However, little is known about its toxicity on bone marrow (BM) cells. In this study, BM cells were treated with EFX and cellular metabolic activity, cell death, the change of neutrophil (CD11b+Gr1+ cells) proportion, and antigen uptake ability of granulocytes were measured. Compared to the control, EFX-treated cells showed the decrease of cellular metabolic activity, the increase of cell death, and the decreased proportion of neutrophils. In contrast, the antigen uptake ability of granulocytes in BM cells was increased by EFX. These data suggest that EFX has only limited toxicity on BM cells. And also, EFX is safe on BM cells in a range of concentration, 6.25 – 25 μg/mL. This study can provide available data for the safety or toxicity of EFX.